Looking To Grow In China’s New Norm? Think Local
This article was originally published in PharmAsia News
Executive Summary
As China steps up regulatory enforcement more affirmatively and forcefully, multinational firms are starting to search for ways to adapt to a slowing economy and increasingly challenging environment. The need to drive growth at a local level is vital to thriving in this “new norm”, says a senior government relations executive.
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Chinese Language Podcast: BIOSECURE Act, US PD-1 Approval, ADC Updates
Guest speaker and lawyer Kevin Duan joins Brian Yang and Dexter Yan to discuss the planned US BIOSECURE Act, the US approval of BeiGene's anti-PD-1 drug and the latest antibody-drug conjugates in development at Chinese pharma firms.
China Biotechs, CDMOs Embrace Uncertain Future, New Options Amid WuXi Woes
The shockwave of WuXi's withdrawal from BIO is ripping through the Chinese contract services sector. While some remain hopeful, others are preparing Plan B.